[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641132":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":38,"centralContacts":43,"locations":10,"responsibleParty":49,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":70,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":10},{"fullName":5,"class":6},"PETHEMA Foundation","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Belantamab mafodotin+Bortezomib+dexamethasone (BVd)",null,"Participants receiving belantamab and dexametahsone plus the proteasome inhibitor Bortezomib as salvage therapy in first or second MM relapse.",[13,14,15],"Drug: Belantamab mafodotin","Drug: Bortezomib","Drug: Dexamethasone",{"label":17,"type":10,"description":18,"interventionNames":19},"Belantamab mafodotin+Pomalidomide-dexamethason (BPd)","Participants receiving belantamab and dexametahsone plus the inmunomadulatory drug Pomalidomide as salvage therapy in first or second MM relapse.",[13,15,20],"Drug: Pomalidomide",[22,27,31,34],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"DRUG","Belantamab mafodotin","All participants evaluated in this study must have received this drug as salvage therapy in first or second relapse. Doses, dose reductions, increased spacing between doses and number of total infusions will be recorded.",[9,17],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"Bortezomib","Participants in BVd arm must have received this drug in combination with belantamab mafodotin in first or second relapse. Doses, dose reductions, increased spacing between doses and number of total infusions will be recorded.",[9],{"type":23,"name":32,"description":25,"armGroupLabels":33,"otherNames":10},"Dexamethasone",[9,17],{"type":23,"name":35,"description":36,"armGroupLabels":37,"otherNames":10},"Pomalidomide","Participants in BPd arm must have received this drug in combination with belantamab mafodotin in first or second relapse. Doses, dose reductions, increased spacing between doses and number of total infusions will be recorded.",[17],[39],{"name":40,"affiliation":41,"role":42},"Javier de la Rubia","Hospital Universitario La Fe","STUDY_CHAIR",[44],{"name":45,"role":46,"phone":47,"phoneExt":10,"email":48},"Carmen López-Carrero","CONTACT","+34916 26 62 32","carmen@fundacionpethema.es",{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100641132","study-to-evaluate-efficacy-and-safety-of-belantamab-based-combinations-for-relapsed-multiple-myeloma-100641132",false,"NCT07637526","Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma","Retrospective Observational Study to Evaluate the Effectiveness and Safety of Belantamab Mafodotin-based Combinations (Belantamab Mafodotin, Bortezomib, Dexamethasone [BVd] or Belantamab Mafodotin, Pomalidomide, Dexamethasone [BPd]) Used as Compassionate Use in Patients With Multiple Myeloma in First or Second Relapse","GEM-BELACOMBOS","Inclusion Criteria:\n\n* Confirmed diagnosis of relapsed\u002Frefractory MM.\n* Having received at least one dose of a belantamab mafodotin combination (BVd or BPd) under compassionate use conditions as treatment for a first or second relapse.\n* Patients ≥18 years of age at the start of treatment with the belantamab mafodotin combination (BVd or BPd) under compassionate use conditions.\n\nExclusion Criteria:\n\n* Any patient who has received a belantamab mafodotin combination (BVd or BPd) under compassionate use conditions in fourth line of treatment or later will be excluded from the study.","ALL","18 Years",{"count":62,"type":63},100,"ESTIMATED","OBSERVATIONAL","The goal of this retrospective observational study is to characterize multiple myeloma (MM) patients (by collecting demographics, disease characteristics and treatment history data) treated in first or second relapse with belantamab mafodotin combinations under compassionate use conditions.",[67],"Relapse Multiple Myeloma",[69],"belantamab mafodotin","NOT_YET_RECRUITING","2026-06-19",{"date":73,"type":74},"2026-06-24","ACTUAL",{"date":76,"type":63},"2026-06-01",{"date":78,"type":63},"2027-12-31",{"name":5,"class":6}]